Introduction Some local protocols suggest using intermediate or therapeutic doses of
anticoagulants for thromboprophylaxis in hospitalized patients with coronavirus disease …

Background Coronavirus disease 2019 (COVID-19) increases thrombosis in hospitalized
patients prompting adoption of different thromboprophylaxis strategies. Safety and efficacy of …

Background Studies report hypercoagulability in coronavirus disease 2019 (COVID‐19),
leading many institutions to escalate anticoagulation intensity for thrombosis prophylaxis …

We conducted a systematic review and a meta-analysis to assess the association of
anticoagulants and their dosage with in-hospital all-cause mortality in COVID-19 patients …

Background There is no current standardized approach to anticoagulation in patients with
Coronavirus Disease 2019 (COVID-19) while potential bleeding risks remain. Our study …

Background The coronavirus disease 2019 (COVID-19) causes extensive coagulopathy and
a potential benefit of anticoagulation therapy has been documented for prevention of …

Background: COVID-19 patients are at high thrombotic risk. The safety and efficacy of
different anticoagulation regimens in COVID-19 patients remain unclear. Methods: We …

Abstract Background Coronavirus Disease 2019 (COVID‐19) is responsible for a worldwide
pandemic, with a high rate of morbidity and mortality. The increasing evidence of an …

Background Anticoagulation in hospitalized COVID-19 patients has been associated with
survival benefit; however, the optimal anticoagulant strategy has not yet been defined. The …

Background Thromboembolic events are common complications of COVID-19. Clinical study
results on safety and efficacy of anticoagulation in COVID-19 are controversial. Material and …